Non-Small Cell Lung Cancer - Market Insight, Epidemiology, and Market Forecast -2034
Key Highlights:
- NSCLC market size has seen a revolutionary change in the last decade owing to the increase in incident cases, continuous uptake of approved therapies, mainly immune checkpoint inhibitors, expected entry of potential premium price emerging therapies, and increasing awareness of mutations like KRAS, BRAF, c-Met, and others. The total market size of NSCLC is estimated to be ~USD 30 billion in the 7MM in 2024.
- The real-world treatment trend depicts a drastic shift toward targeted and immunotherapies (from only systemic therapies in the past), which is expected to contribute the most now.
- NSCLC is increasingly becoming a biomarker-driven market. EGFR is one of the profitable biomarker segment, with blockbuster therapies such as TAGRISSO. TAGRISSO is now the dominant EGFR inhibitor selling nearly USD 6 billion annually. The prevalence of patients with this resistance mutation has increased since TAGRISSO was authorized for use in the first line. The post-TAGRISSO setting is one of the highest areas of unmet need.
- At present, ALECENSA and ALUNBRIG are the preferred first-line ALK TKIs. ALECENSA is much more widely used compared to ALUNBRIG and dominate the ALK market. Prior to entry of ALECENSA and ALUNBRIG, XALKORI was the first-line treatment choice in ALK patients.
- ADCs are a class of oncology medications that are among the most rapidly expanding. Despite the outstanding patient responses that conventional ADCs have produced, they have only been tested on patients with the highest target expression levels and a narrow number of targets. Although only one ADC is approved for NSCLC, and it is only for a limited subgroup (HER2m NSCLC), companies are attempting to target a larger NSCLC population, particularly in areas where KEYTRUDA is the market leader. Among the upcoming therapies in the 7MM, Dato-DXd is expected to capture a significant market size of patients expressing PD-L1.
- As per DelveInsight's analysis, the total incident cases of NSCLC in the 7MM were approximately 204,800 in 2024; these cases are estimated to increase by 2034.
- Various types of mutations are commonly observed in NSCLC. There is mounting evidence that substantial molecular and clinical heterogeneity exists within oncogenic driver-defined subgroups of NSCLC. The most frequent biomarkers are EGFR in Japan and KRAS in the US and Europe.
- EGFR exon 19 deletions and Exon 21 L858R substitution (sensitizing mutations) account for approximately 80% of EGFR mutations in NSCLC.
- The most frequent KRAS variant observed in NSCLC is G12C. In the US, KRASG12C is present in ~37% of NSCLC cases.
- HAIYITAN's recent approval by the PMDA positions it as a significant player in Japan's growing c-MET inhibitor market. Its regulatory success enhances credibility and sets the stage for rapid adoption in treating cancers with c-MET alterations, particularly in a market where precision oncology is expanding.
- In BRAF mutation, TAFINLAR + MEKINIST combination has led the market since its 2021 launch, driven by its strong clinical performance
- Due to their rarity and the lack of late-stage clinical studies, the treatment paradigm for rare NSCLC mutations is less clear. Rare biomarkers like ROS-1, HER2, RET fusion, and NTRK1/2/3 Gene fusion have seen a lot of progress in past few years.
- Among EU4, Germany accounted for the highest number of NSCLC cases in 2024, whereas Spain accounted for the lowest cases in 2024.
DelveInsight's "Non-small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of top oncogenic drivers/biomarkers in NSCLC (such as EGFR, c-MET, ROS1, KRAS, ALK, HER2, BRAF, RET fusion, NRG1 fusion, NTRK1/2/3 gene fusion, PD-L1, etc.), historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
NSCLC market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM NSCLC market size from 2020 to 2034. The report also covers current NSCLC treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
NSCLC Understanding and Treatment Algorithm
NSCLC Overview and Diagnosis
NSCLC is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. Early diagnosis offers the best prognosis for NSCLC. However, NSCLC and other lung cancers can be difficult to diagnose because these cancers often have symptoms mistaken for common illnesses or the effects of long-term smoking. Because of this, 80% of people diagnosed with NSCLC have already progressed to advanced stages, making it more difficult to treat. If lung cancer is suspected, the physician will recommend imaging tests (CT, PET, or MRI scans) to identify abnormalities in and around the lungs. The physician may also examine a sample of mucus under the microscope.
If these initial tests identify cancer, a lung biopsy can be conducted. A bronchoscopy can also be recommended, allowing the physician to visualize and remove tissue. If lung cancer is confirmed, genetic testing can be done on the lung tissue to identify details about the cancer that can help inform treatment.
NSCLC Treatment
Treatment options and recommendations depend on several factors, including the type and stage of cancer, possible side effects, and the patient's preferences and overall health. The most common treatments for NSCLC are:
- Surgery
- Radiotherapy
- Chemotherapy
- Chemotherapy with radiotherapy (chemoradiotherapy)
- Immunotherapy
- Targeted cancer drugs
NSCLC Epidemiology
The NSCLC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of NSCLC, gender-specific cases of NSCLC, age-specific cases of NSCLC, total incident cases of NSCLC by histology, total cases of NSCLC by stages, total incident cases of NSCLC by genetic mutation/biomarkers, Line wise Treated Cases of Metastatic NSCLC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
- About 10-15% of all lung cancers are SCLC, and about 80-85% are Non-Small Cell Lung Cancer.
- In the US, in 2024, there were approximately 204,800 new cases of NSCLC cancer (~115,500 in men and ~89,300 in women.
- The three main histological subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the US, approximately 59% of all lung cancers are adenocarcinomas. About 25% of all lung cancers are squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 6% of all lung cancers.
- Among the age-specific contribution, age =65 years are affected more by NSCLC than age <65 years. In 2024, there were ~140,000 of NSCLC in age =65 years in the US.
- In 2024, the total incident cases of NTRK1/2/3 gene fusion NSCLC in the US was around 450.
- In biomarker specific specific cases, most number of cases is from PD-L1 followed by KRAS, EGFR. On the other hand, NTRK accounted for least number of cases whereas, BRAF accounted for approximately 5% cases.
- The two main subtypes of KRAS NSCLC are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the United States, ~4,900 comprised of KRAS G12C, and ~13,300 comprised of KRAS non-G12C in 2024.
NSCLC Drug Chapters
The drug chapter segment of the NSCLC report encloses a detailed analysis of NSCLC marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the NSCLC pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Marketed Drugs
KEYTRUDA (pembrolizumab): Merck
KEYTRUDA is a PD-1-blocking antibody. It is mainly used for advanced cancers that have spread to other body parts or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-L1. KEYTRUDA was first approved in October 2015 by the US FDA as a monotherapy for metastatic NSCLC. Later, the labels were expanded in 2016, 2017, 2018, and in 2023. In October 2023, the FDA approved KEYTRUDA platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent KEYTRUDA as post-surgical adjuvant treatment for resectable (tumors =4 cm or node positive) NSCLC. The drug has also received approvals in EU4 and the UK (August 2016) and Japan (December 2016), where the labels were expanded as well. Recently in September 2024, Merck announced that the MHLW has approved new indications for KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment. Earlier in March 2024, Merck announced that the EC has approved KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment
In December 2024, Merck announced that it is discontinuing the Phase III KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with NSCLC, based on the recommendation of an independent Data Monitoring Committee (DMC).
TECENTRIQ (atezolizumab): Genentech/Roche
TECENTRIQ is a PD-L1-blocking antibody. It is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin with a calculated molecular mass of 145 kDa. According to Roche's recent product development portfolio published in October 2024, the company anticipates submitting a filing for TECENTRIQ in the periadjuvant treatment of NSCLC in 2025.
TECENTRIQ was initially approved by the US FDA for the treatment of people with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities in October 2016. Later, the company expanded the label in 2018, 2019, 2020, 2021, and 2024. The drug was also approved in the EU (September 2017) and in Japan (April 2018) for the treatment of NSCLC. Recently, in September 2024, the US FDA approved TECENTRIQ and HYBREZA (hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for SC, under the skin injection for patients in the US.
Emerging Drugs
Telisotuzumab vedotin: AbbVie
Teliso-V is an investigational antibody-drug conjugate targeting c-Met, a receptor tyrosine kinase overexpressed in tumors, including Non-small Cell Lung Cancer. Teliso-V has the potential to become an important new treatment option in non-small cell lung cancer, with an anticipated approval in 2L+ NSCLC in 2024. In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy. In May 2022, AbbVie initiated a Phase III clinical trial to evaluate Teliso-V versus docetaxel for the treatment of patients with previously treated c-Met overexpressing, epidermal growth factor receptor wild type, and advanced/metastatic non-squamous NSCLC.
Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of the most advanced programs in AstraZeneca's ADC scientific platform and one of the three leading ADCs in the oncology pipeline of Daiichi Sankyo. In January 2023, a Phase III clinical trial, combined with immune checkpoint inhibitors for the first-line treatment for Non-Small Cell Lung Cancer without actionable genomic alterations, PD-L1 <50% (trial name: TROPION-Lung07), was initiated. No TROP2-directed therapies are currently approved for treating Non-Small Cell Lung Cancer patients. AstraZeneca and Daiichi Sankyo are interrogating Dato-DXd in 1L non-driver mutation patients with TROPION-Lung08 (trying to knock off the Keynote-024 regimen) and with TROPION-Lung07 (trying to dethrone Keynote-189 regimen, the most important indication for Merck's KEYRTUDA), as well as covering 2L and 3L patients with TROPION-Lung01. In December 2024, Daiichi Sankyo announced Dato-DXd has been granted BTD in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC with disease progression on or after treatment with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
Drug Class Insights
The existing NSCLC treatment is mainly dominated by targeted therapies for mutations such as EGFR-sensitizing mutations, EGFR exon 20 insertions, ALK fusions, ROS1 fusions, BRAFV600E mutation, MET exon 14 skipping mutations, RET fusions, and KRASG12C mutation.
EGFR mutations and ALK rearrangements are well-known genetic abnormalities that drive the development of NSCLC. The use of TKIs as a treatment approach has shown better results in terms of patient outcomes when compared to chemotherapy.
EGFR mutations are frequently observed, EGFR exon 19 deletions and EGFR exon 21 L858R mutations. The FDA has approved various TKIs to treat these mutations, with TAGRISSO considered the standard treatment. GILOTRIF is approved for patients with other EGFR sensitivity mutations like S768I, L861Q, and G719X. However, approximately 8-10% of EGFR mutations involve exon 20 insertions, which do not respond to treatments targeting exon 19 or 21 alterations, including osimertinib. Currently, three targeted therapies, RYBREVANT, TAGRISSO and EXKIVITY, are approved for EGFR. Later EXKIVITY were withdrawn from the market. These mutations represent an area of unmet medical need in NSCLC. While treatment with EGFR TKIs effectively eliminates most cancer cells, a small population of drug-tolerant cells may persist. These cells can remain inactive and undetectable for extended periods but eventually resume growth and spread to other body parts.
NSCLC Market Outlook
As more targetable mutations are discovered, and new targeted drugs are developed, patients and oncologists will have an expanding array of treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure sufficient data supports the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy.
Previously, molecular-based treatments were limited to advanced-stage Non-small Cell Lung Cancer. However, recent findings have demonstrated their efficacy in early-stage and locally advanced disease. New studies have explored therapies targeting a wider range of oncogenes, aiming to overcome drug resistance and provide treatment options for patients previously excluded from clinical trials for advanced-stage lung cancer. The emerging data from these ongoing trials are expected to influence future treatment guidelines and foster the adoption of personalized medicine. As a result, a continuous evolution of the treatment landscape is anticipated, ultimately leading to improved survival rates and enhanced quality of life for lung cancer patients.
PD-L1 Expression
With more than 500,000 cases in the 7MM region, lung cancer is one of the leading causes of death worldwide. This condition is often diagnosed when the patient reaches the advanced, inoperable, or metastatic stage, adversely affecting their quality of life.
Till the last decade, chemotherapy was used as the standard of care in the advanced and metastatic stages until the first ICI 'KEYTRUDA (pembrolizumab)' got approved in 2015 as a second-line treatment option for such advanced patients; a similar path was followed by TECENTRIQ (atezolizumab) who entered the market in 2016. These therapies entered the first-line domain after 2016 and expanded their labels by expanding the targetable pool. Recently, in 2020, OPDIVO (nivolumab) + ipilimumab was approved as a 1L treatment for patients with metastatic NSCLC.
EGFR Mutation
The treatment of EGFR-mutant NSCLC has been transformed by the development of targeted therapies in the last two decades; however, choosing the best therapy after EGFR TKIs fail is still a challenge. There are five EGFR tyrosine kinase inhibitors (TKIs) approved for first-line treatment of advanced NSCLC with common EGFR-sensitizing mutations (e.g., EGFR exon 19 deletions or exon 21 mutations [L858R]): erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib. These drugs have different efficacy and safety profiles and are classified as first- (e.g., erlotinib, gefitinib), second- (e.g., afatinib, dacomitinib), or third-generation (e.g., osimertinib) TKIs. Afatinib and osimertinib, which are second- and third-generation TKIs, respectively, have shown prolonged activity against some rare EGFR mutations (e.g., T790M [osimertinib], G719X, L861Q, or S768I [afatinib and osimertinib]).
Key players, such as AstraZeneca, Bristol Myers Squibb, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly, Immutep, Sanofi, GlaxoSmithKline, and others, are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products to treat Non-Small Cell Lung Cancer.
- The total market size of PD-L1 expressing NSCLC is estimated to be ~USD 15,000 million by 2024 in the 7MM, followed by EGFR and KRAS.
- The total market size in the US for EGFR NSCLC was estimated to be nearly USD 2,900 million in 2024, which is expected to increase due to the launch of emerging therapies and label expansion of current therapies.
- Alectinib is a common second ALK TKI used after crizotinib progression in 1st line of treatment. In 2024, Alectinib captured ~50% market share of the ALK market in the US.
- Lorlatinib is a third-generation ALK inhibitor that generated ~USD 440 million in 2024 in the 7MM.
- PD-L1 therapies are mainly utilized in patients without genetic drivers. Merck's KEYTRUDA is generally considered the 'gold standard' of care in 1L NSCLC when combined with platinum-chemotherapy, regardless of PD-1 status.
- ENHERTU's uptake in HER2m NSCLC is strong, but ROZLYTREK and GAVRETO in RET-fusion are performing below sales expectations.
NSCLC Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.
By overcoming the resistance from first and second-generation EGFR inhibitors and better efficacy in terms of overall response and progression-free survival, TAGRISSO become the market leader in the EGFR NSCLC market with fast uptake.
Lorlatinib is a third-generation ALK inhibitor. It showed higher potency and selectivity for ALK mutation, better penetration into the brain, and broader activity against different resistance mutations compared to the previous generation ALK inhibitor. Its uptake is fast compared to alectinib. However, by 2034, the highest market size will be captured by alectinib.
NSCLC Activities
The report provides insights into therapeutic candidates in Phase III and II. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for NSCLC emerging therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Medical Oncologists, Pulmonologists and Professors, Chief of the Thoracic Service at the Memorial Sloan Kettering Cancer Center, and Others.
DelveInsight's analysts connected with 40+ KOLs to gather insights; however, interviews were conducted with 18+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Texas, UT Southwestern Medical Center in Dallas, Cancer Research UK Barts Centre in London, LUNGevity Foundation, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Non-Small Cell Lung Cancer market trends.
We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Market Access and Reimbursement
The cost of treating NSCLC has shown significant increases over time, irrespective of the stage of the disease. According to real-world findings, this is particularly true for younger patients treated in the outpatient setting. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries for other registered therapies-even for ALK inhibitors and checkpoint inhibitors in first-line-there were apparent gaps in availability and/or reimbursement.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
- The report covers a segment of key events, an executive summary, and a descriptive overview of NSCLC, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current treatment landscape.
- A detailed review of the NSCLC market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM NSCLC market.
NSCLC Report Insights
- Patient Population
- Therapeutic Approaches
- NSCLC Pipeline Analysis
- NSCLC Market Size and Trends
- Existing and future Market Opportunity
NSCLC Report Key Strengths
- Ten Years Forecast
- 7MM Coverage
- NSCLC Epidemiology Segmentation
- Key Cross Competition
- Conjoint analysis
- Drugs Uptake and Key Market Forecast Assumptions
NSCLC Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
FAQs:
- What is the historical and forecasted NSCLC patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
- What was the NSCLC total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors for this growth?
- How will different NSCLC target classes affect the treatment paradigm of NSCLC?
- What will be the impact of KEYTRUDA's expected patent expiry?
- How will KEYTRUDA compete with other therapies in the first- and second lines?
- Which class is going to be the largest contributor in 2034?
- What are the pricing variations among different geographies for approved and off-label therapies?
- Although multiple expert guidelines recommend testing for targetable mutations prior to therapy initiation, why do barriers to testing remain high?
- What are the current and emerging options for treating NSCLC?
- How many companies are developing therapies to treat NSCLC?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies?
Reasons to buy:
- The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the NSCLC Market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
- Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
- Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
- Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
- To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. KEY HIGHLIGHTS
4. EXECUTIVE SUMMARY
5. METASTATIC NSCLC MARKET OVERVIEW AT A GLANCE
- 5.1. MARKET SHARE (%) DISTRIBUTION BY IMMUNE/MOLECULAR BIOMARKER IN 2020
- 5.2. MARKET SHARE (%) DISTRIBUTION BY IMMUNE/MOLECULAR BIOMARKER IN 2034
6. KEY EVENTS
7. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
8. DISEASE BACKGROUND AND OVERVIEW
- 8.1. INTRODUCTION
- 8.1.1. Cellular Classification of NSCLC
- 8.1.2. Signs and Symptoms of NSCLC
- 8.1.3. Risk Factors of Lung Cancer
- 8.1.4. Causes of NSCLC
- 8.1.5. Disease Biology: NSCLC
- 8.1.5.1. Genomic Alterations
- 8.1.5.2. Tumor Microenvironment
9. DIAGNOSIS OF NSCLC
- 9.1. STAGES OF NSCLC
- 9.2. STAGING SYSTEM
10. CURRENT TREATMENT PRACTICES: NSCLC
- 10.1. CHEMOTHERAPY
- 10.2. TARGETED THERAPY
- 10.3. IMMUNOTHERAPY
- 10.4. SURGERY
- 10.5. RADIATION THERAPY
- 10.6. STAGE-WISE TREATMENT OPTIONS OF NSCLC
11. TREATMENT GUIDELINES AND RECOMMENDATIONS FOR NON-SMALL CELL LUNG CANCER (NSCLC)
- 11.1. NCCN GUIDELINE FOR NSCLC (2025)
- 11.2. ESMO GUIDELINE FOR NSCLC
- 11.2.1. Non-oncogene-addicted metastatic NSCLC: ESMO Clinical Practice Guidelines for Treatment
- 11.2.2. Oncogene-addicted Metastatic NSCLC: ESMO Clinical Practice Guidelines for Treatment.
- 11.3. JAPANESE GUIDELINES FOR NSCLC AT THE JAPAN LUNG CANCER SOCIETY (2024)
- 11.4. BIOMARKERS TESTING RECOMMENDATIONS
12. EPIDEMIOLOGY AND PATIENT POPULATION
- 12.1. KEY FINDINGS
- 12.2. ASSUMPTIONS AND RATIONALE
- 12.3. TOTAL INCIDENT CASES OF NSCLC IN THE 7MM
- 12.4. UNITED STATES
- 12.4.1. Total Incident Cases of NSCLC in the United States
- 12.4.2. Gender-specific Cases of NSCLC in the United States
- 12.4.3. Age-specific Cases of NSCLC in the United States
- 12.4.4. Total Incident Cases of NSCLC by Histology in the United States
- 12.4.5. Total Incident Cases of NSCLC by Stage in the United States
- 12.4.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States
- 12.4.7. Line wise Treated Cases of Metastatic NSCLC in the United States
- 12.5. EU4 AND THE UK
- 12.5.1. Total Incident Cases of NSCLC in EU4 and the UK
- 12.5.2. Gender-specific Cases of NSCLC in EU4 and the UK
- 12.5.3. Age-specific Cases of NSCLC in EU4 and the UK
- 12.5.4. Total Incident Cases of NSCLC by Histology in EU4 and the UK
- 12.5.5. Total Incident Cases of NSCLC by Stage in EU4 and the UK
- 12.5.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK
- 12.5.7. Line wise Treated Cases of Metastatic NSCLC in EU4 and the UK
- 12.6. JAPAN EPIDEMIOLOGY
- 12.6.1. Total Incident Cases of NSCLC in Japan
- 12.6.2. Gender-specific Cases of NSCLC in Japan
- 12.6.3. Age-specific Cases of NSCLC in Japan
- 12.6.4. Total Incident Cases of NSCLC by Histology in Japan
- 12.6.5. Total Incident Cases of NSCLC by Stage in Japan
- 12.6.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan
- 12.6.7. Line wise Treated Cases of Metastatic NSCLC in Japan
13. PATIENT JOURNEY
14. KEY ENDPOINTS IN NSCLC
15. MARKETED DRUGS
- 15.1. KEY COMPETITORS
- 15.2. GILOTRIF/GIOTRIF (AFATINIB MALEATE): BOEHRINGER INGELHEIM
- 15.2.1. Product Description
- 15.2.2. Regulatory Milestones
- 15.2.3. Other Developmental Activities
- 15.2.4. Pivotal Clinical Trial
- 15.2.5. Safety and Efficacy
- 15.2.6. Product Profile
- 15.3. RYBREVANT (AMIVANTAMAB): JOHNSON & JOHNSON INNOVATIVE MEDICINE (JANSSEN)
- 15.3.1. Product Description
- 15.3.2. Regulatory Milestones
- 15.3.3. Other Developmental Activities
- 15.3.4. Pivotal Clinical Trial
- 15.3.5. Current Pipeline Activity
- 15.3.5.1. Clinical Trials Information
- 15.3.6. Safety and Efficacy
- 15.3.7. Product Profile
- 15.4. EXKIVITY (MOBOCERTINIB): TAKEDA PHARMACEUTICALS
- 15.4.1. Product Description
- 15.4.2. Regulatory Milestones
- 15.4.3. Other Developmental Activities
- 15.4.4. Pivotal Clinical Trial
- 15.4.5. Current Pipeline Activity
- 15.4.5.1. Clinical Trials Information
- 15.4.6. Safety and Efficacy
- 15.4.7. Product Profile
- 15.5. PORTRAZZA (NECITUMUMAB): ELI LILLY AND COMPANY
- 15.5.1. Product Description
- 15.5.2. Regulatory Milestones
- 15.5.3. Other Developmental Activities
- 15.5.4. Pivotal Clinical Trial
- 15.5.5. Safety and Efficacy
- 15.5.6. Product Profile
- 15.6. TEPMETKO (TEPOTINIB): EMD SERONO (MERCK KGAA)
- 15.6.1. Product Description
- 15.6.2. Regulatory Milestones
- 15.6.3. Other Developmental Activities
- 15.6.4. Pivotal Clinical Trial
- 15.6.5. Current Pipeline Activity
- 15.6.5.1. Clinical Trials Information
- 15.6.6. Safety and Efficacy
- 15.6.7. Product Profile
- 15.7. RETEVMO/RETSEVMO (SELPERCATINIB): ELI LILLY AND COMPANY
- 15.7.1. Product Description
- 15.7.2. Regulatory Milestones
- 15.7.3. Other Developmental Activities
- 15.7.4. Pivotal Clinical Trial
- 15.7.5. Current Pipeline Activity
- 15.7.5.1. Clinical Trials Information
- 15.7.6. Safety and Efficacy
- 15.7.7. Product Profile
- 15.8. GAVRETO (PRALSETINIB): BLUEPRINT MEDICINES/RIGEL PHARMACEUTICALS
- 15.8.1. Product Description
- 15.8.2. Regulatory Milestones
- 15.8.3. Other Developmental Activities
- 15.8.4. Pivotal Clinical Trial
- 15.8.5. Current Pipeline Activity
- 15.8.5.1. Clinical Trials Information
- 15.8.6. Product Profile
- 15.9. KEYTRUDA (PEMBROLIZUMAB): MERCK
- 15.9.1. Product Description
- 15.9.2. Regulatory Milestones
- 15.9.3. Other Developmental Activities
- 15.9.4. Pivotal Clinical Trial
- 15.9.5. Current Pipeline Activity
- 15.9.5.1. Clinical Trials Information
- 15.9.6. Safety and Efficacy
- 15.9.7. Product Profile
16. EMERGING DRUGS
- 16.1. FIRMONERTINIB: ARRIVENT BIOPHARMA
- 16.1.1. Product Description
- 16.1.2. Other Developmental Activities
- 16.1.3. Clinical Development
- 16.1.3.1. Clinical Trials Information
- 16.1.4. Safety and Efficacy
- 16.2. BELRESTOTUG (EOS-448) + JEMPERLI (DOSTARLIMAB): ITEOS THERAPEUTICS AND GSK
- 16.2.1. Product Description
- 16.2.2. Other Developmental Activities
- 16.2.3. Clinical Development
- 16.2.3.1. Clinical Trials Information
- 16.3. SACITUZUMAB TIRUMOTECAN (MK-2870): MERCK AND KELUN-BIOTECH
- 16.3.1. Product Description
- 16.3.2. Other Developmental Activities
- 16.3.3. Clinical Development
- 16.3.3.1. Clinical Trials Information
- 16.3.4. Safety and Efficacy
- 16.4. TRODELVY (SACITUZUMAB GOVITECAN): GILEAD SCIENCES
- 16.4.1. Product Description
- 16.4.2. Other Developmental Activities
- 16.4.3. Clinical Development
- 16.4.3.1. Clinical Trial Information
- 16.4.4. Safety and Efficacy
- 16.5. PYROTINIB: JIANGSU HENGRUI MEDICINE
- 16.5.1. Product Description
- 16.5.2. Clinical Development
- 16.5.2.1. Clinical Trial Information
- 16.6. OCIPERLIMAB (BGB-A1217): BIEGENE
- 16.6.1. Product Description
- 16.6.2. Other Developmental Activities
- 16.6.3. Clinical Development
- 16.6.3.1. Clinical Trial Information
- 16.6.4. Safety and Efficacy
- 16.7. VOLRUSTOMIG (MEDI5752): ASTRAZENECA
- 16.7.1. Product Description
- 16.7.2. Other Developmental Activities
- 16.7.3. Clinical Development
- 16.7.3.1. Clinical Trial Information
- 16.7.4. Safety and Efficacy
- 16.8. GOTISTOBART (BNT316): ONCOC4/BIONTECH
- 16.8.1. Product Description
- 16.8.2. Other Developmental Activities
- 16.8.3. Clinical Development
- 16.8.3.1. Clinical Trials Information
- 16.8.4. Safety and Efficacy
- 16.9. IVONESCIMAB (AK112): AKESO BIOPHARMA/SUMMIT THERAPEUTICS
- 16.9.1. Product Description
- 16.9.2. Other Developmental Activity
- 16.9.3. Clinical Development
- 16.9.3.1. Clinical Trials Information
- 16.9.4. Safety and Efficacy
- 16.1. ZYNYZ (RETIFANLIMAB-DLWR): INCYTE/MACROGENICS
- 16.10.1. Product Description
- 16.10.2. Other Developmental Activities
- 16.10.3. Clinical Development
- 16.10.3.1. Clinical Trials Information
- 16.10.4. Safety and Efficacy
- 16.12. ZEJULA (NIRAPARIB): GLAXOSMITHKLINE
- 16.12.1. Product Description
- 16.12.2. Other Developmental Activities
- 16.12.3. Clinical Development
- 16.12.3.1. Clinical Trial Information
- 16.12.4. Safety and Efficacy
- 16.13. SAVOLITINIB: ASTRAZENECA/HUTCHISON MEDIPHARMA
- 16.13.1. Product Description
- 16.13.2. Other Developmental Activities
- 16.13.3. Clinical Development
- 16.13.3.1. Clinical Trials Information
- 16.13.4. Safety and Efficacy
- 16.14. DIVARASIB (GDC-6036): HOFFMANN-LA ROCHE /GENENTECH
- 16.14.1. Product Description
- 16.14.2. Other Developmental Activities
- 16.14.3. Clinical Development
- 16.14.3.1. Clinical Trials Information
- 16.14.4. Safety and Efficacy
- 16.15. TIRAGOLUMAB (RG6058): HOFFMANN-LA ROCHE
- 16.15.1. Product Description
- 16.15.2. Other Developmental Activities
- 16.15.3. Clinical Development
- 16.15.3.1. Clinical Trial Information
- 16.15.4. Safety and Efficacy
- 16.16. RILVEGOSTOMIG (AZD2936): ASTRAZENECA
- 16.16.1. Product Description
- 16.16.2. Other Developmental Activities
- 16.16.3. Clinical Development
- 16.16.3.1. Clinical Trials Information
- 16.16.4. Safety and Efficacy
- 16.17. JEMPERLI (DOSTARLIMAB): GLAXOSMITHKLINE AND ANAPTYSBIO
- 16.17.1. Product Description
- 16.17.2. Other Developmental Activities
- 16.17.3. Clinical Development
- 16.17.3.1. Clinical Trial Information
- 16.17.4. Safety and Efficacy
- 16.18. SERPLULIMAB (HLX10): SHANGHAI HENLIUS BIOTECH
- 16.18.1. Product Description
- 16.18.2. Other Developmental Activities
- 16.18.3. Clinical Development
- 16.18.3.1. Clinical Trial Information
- 16.18.4. Safety and Efficacy
- 16.19. MK-1084: OTSUKA PHARMACEUTICAL
- 16.19.1. Product Description
- 16.19.2. Other Developmental Activities
- 16.19.3. Clinical Development
- 16.19.3.1. Clinical Trials Information
- 16.19.4. Safety and Efficacy
- 16.2. OPDUALAG (NIVOLUMAB AND RELATLIMAB): BRISTOL-MYERS SQUIBB
- 16.20.1. Product Description
- 16.20.2. Other Developmental Activities
- 16.20.3. Clinical Development
- 16.20.3.1. Clinical Trial Information
- 16.20.4. Safety and Efficacy
- 16.21. TEDOPI: OSE IMMUNOTHERAPEUTICS
- 16.21.1. Product Description
- 16.21.2. Other Developmental Activities
- 16.21.3. Clinical Development
- 16.21.3.1. Clinical Trial Information
- 16.21.4. Safety and Efficacy
- 16.22. DOMVANALIMAB: ARCUS BIOSCIENCES AND GILEAD SCIENCES
- 16.22.1. Product Description
- 16.22.2. Other Developmental Activities
- 16.22.3. Clinical Development
- 16.22.3.1. Clinical Trial Information
- 16.22.4. Safety and Efficacy
- 16.23. SIGVOTATUG VEDOTIN (PF08046047/SGN-B6A): PFIZER
- 16.23.1. Product Description
- 16.23.2. Other Developmental Activities
- 16.23.3. Clinical Development
- 16.23.3.1. Clinical Trials Information
- 16.23.4. Safety and Efficacy
- 16.24. CERALASERTIB (AZD6738): ASTRAZENECA
- 16.24.1. Product Description
- 16.24.2. Clinical Development
- 16.24.2.1. Clinical Trials Information
- 16.24.3. Safety and Efficacy
- 16.25. ZIPALERTINIB (CLN-081): CULLINAN ONCOLOGY/TAIHO PHARMA
- 16.25.1. Product Description
- 16.25.2. Other Developmental Activities
- 16.25.3. Clinical Development
- 16.25.3.1. Clinical Trials Information
- 16.25.4. Safety and Efficacy
- 16.26. ANKTIVA (N-803, NOGAPENDEKIN ALFA INBAKICEPT-PMLN): IMMUNITYBIO
- 16.26.1. Product Description
- 16.26.2. Other Developmental Activities
- 16.26.3. Clinical Development
- 16.26.3.1. Clinical Trials Information
- 16.26.4. Safety and Efficacy
- 16.27. AMEILE (AUMOLERTINIB,ALMONERTINIB,HS-10206): JIANGSU HANSOH PHARMACEUTICAL
- 16.27.1. Product Description
- 16.27.2. Other Developmental Activity
- 16.27.3. Clinical Development
- 16.27.3.1. Clinical Trials Information
- 16.27.4. Safety and Efficacy
- 16.28. TELISOTUZUMAB VEDOTIN (ABBV-399, TELISO-V): ABBVIE
- 16.28.1. Product Description
- 16.28.2. Other Developmental Activities
- 16.28.3. Clinical Development
- 16.28.3.1. Clinical Trials Information
- 16.28.4. Safety and Efficacy
- 16.29. DATOPOTAMAB DERUXTECAN: DAIICHI SANKYO/ASTRAZENECA
- 16.29.1. Product Description
- 16.29.2. Other Developmental Activities
- 16.29.3. Clinical Development
- 16.29.3.1. Clinical Trial Information
- 16.29.4. Safety and Efficacy
- 16.3. ZONGERTINIB (BI-1810631): BOEHRINGER INGELHEIM
- 16.30.1. Product Description
- 16.30.2. Other Development Activity
- 16.30.3. Clinical Development
- 16.30.3.1. Clinical Trial Information
- 16.30.4. Safety and Efficacy
- 16.31. BAY 2927088: BAYER
- 16.31.1. Product Description
- 16.31.2. Other Development Activity
- 16.31.3. Clinical Development
- 16.31.3.1. Clinical Trial Information
- 16.31.4. Safety and Efficacy
- 16.32. MRNA-4157 (V940): MODERNA THERAPEUTICS/MERCK SHARP & DOHME
- 16.32.1. Product Description
- 16.32.2. Other Developmental Activities
- 16.32.3. Clinical Development
- 16.32.3.1. Clinical Trials Information
- 16.33. PATRITUMAB DERUXTECAN: DAIICHI SANKYO/ASTRAZENECA
- 16.33.1. Product Description
- 16.33.2. Other Developmental Activities
- 16.33.3. Clinical Development
- 16.33.3.1. Clinical Trials Information
- 16.33.4. Safety and Efficacy
- 16.34. OLOMORASIB (LY3537982): ELI LILLY AND COMPANY
- 16.34.1. Product Description
- 16.34.2. Other Developmental Activities
- 16.34.3. Clinical Development
- 16.34.3.1. Clinical Trials Information
- 16.34.4. Safety and Efficacy
- 16.35. PLINABULIN + DOCETAXEL: BEYONDSPRING
- 16.35.1. Product Description
- 16.35.2. Other Developmental Activities
- 16.35.3. Clinical Development
- 16.35.3.1. Clinical Trials Information
- 16.35.4. Safety and Efficacy
- 16.36. EFTILAGIMOD ALPHA (EFTI, IMP321): IMMUTEP
- 16.36.1. Product Description
- 16.36.2. Other Developmental Activities
- 16.36.3. Clinical Development
- 16.36.3.1. Clinical Trials Information
- 16.36.4. Safety and Efficacy
- 16.37. ACASUNLIMAB (BNT311): GENMAB
- 16.37.1. Product Description
- 16.37.2. Other Developmental Activities
- 16.37.3. Clinical Development
- 16.37.3.1. Clinical Trials Information
- 16.37.4. Safety and Efficacy
- 16.38. SUNVOZERTINIB (DZD9008): DIZAL PHARMACEUTICAL
- 16.38.1. Product Description
- 16.38.2. Other Developmental Activities
- 16.38.3. Clinical Development
- 16.38.3.1. Clinical Trials Information
- 16.38.4. Safety and Efficacy
- 16.39. FIANLIMAB (REGN3767): REGENERON PHARMACEUTICALS
- 16.39.1. Product Description
- 16.39.2. Clinical Development
- 16.39.2.1. Clinical Trial Information
- 16.4. COBOLIMAB: GLAXOSMITHKLINE
- 16.40.1. Product Description
- 16.40.2. Other Developmental Activities
- 16.40.3. Clinical Development
- 16.40.3.1. Clinical Trial Information
- 16.40.4. Safety and Efficacy
- 16.41. LIVMONIPLIMAB (ARGX-115): ABBVIE
- 16.41.1. Product Description
- 16.41.2. Other Developmental Activities
- 16.41.3. Clinical Development
- 16.41.3.1. Clinical Trials Information
- 16.41.4. Safety and Efficacy
- 16.42. DOVBLERON (TALETRECTINIB): NUVATION BIO/INNOVENT BIOLOGICS/DAIICHI SANKYO/NIPPON KAYAKU
- 16.42.1. Product Description
- 16.42.2. Other Developmental Activities
- 16.42.3. Clinical Development
- 16.42.3.1. Clinical Trials Information
- 16.42.4. Safety and Efficacy
- 16.43. AMTAGVI (LN-145): IOVANCE BIOTHERAPEUTICS
- 16.43.1. Product Description
- 16.43.2. Other Developmental Activities
- 16.43.3. Clinical Development
- 16.43.3.1. Clinical Trials Information
- 16.43.4. Safety and Efficacy
- 16.44. BNT327 (PM8002) BIOTHEUS/BIONTECH
- 16.44.1. Product Description
- 16.44.2. Other Developmental Activities
- 16.44.3. Clinical Development
- 16.44.3.1. Clinical Trials Information
- 16.45. CAN-2409 (AGLATIMAGENE BESADENOVEC): CANDEL THERAPEUTICS
- 16.45.1. Product Description
- 16.45.2. Other Developmental Activities
- 16.45.3. Clinical Development
- 16.45.3.1. Clinical Trials Information
- 16.45.4. Safety and Efficacy
- 16.46. MECBOTAMAB VEDOTIN (BA3011, CAB-AXL-ADC): BIOATLA
- 16.46.1. Product Description
- 16.46.2. Other Developmental Activities
- 16.46.3. Clinical Development
- 16.46.3.1. Clinical Trials Information
- 16.46.4. Safety and Efficacy
- 16.47. BEMCENTINIB: BERGENBIO/RIGEL PHARMACEUTICALS
- 16.47.1. Product Description
- 16.47.2. Other Developmental Activities
- 16.47.3. Clinical Development
- 16.47.3.1. Clinical Trials Information
- 16.47.4. Safety and Efficacy
- 16.48. IO102-IO103: IO BIOTECH
- 16.48.1. Product Description
- 16.48.2. Other Developmental Activities
- 16.48.3. Clinical Development
- 16.48.3.1. Clinical Trials Information
- 16.48.4. Safety and Efficacy
- 16.49. IBI363: INNOVENT BIOLOGICS
- 16.49.1. Product Description
- 16.49.2. Other Developmental Activities
- 16.49.3. Clinical Development
- 16.49.3.1. Clinical Trial Information
- 16.49.4. Safety and Efficacy
- 16.5. VEBRELTINIB (APL-101): APOLLOMICS
- 16.50.1. Product Description
- 16.50.2. Other Developmental Activities
- 16.50.3. Clinical Development
- 16.50.3.1. Clinical Trials Information
- 16.50.4. Safety and Efficacy
- 16.51. LP-300: LANTERN PHARMA
- 16.51.1. Product Description
- 16.51.2. Other Developmental Activities
- 16.51.3. Clinical Development
- 16.51.3.1. Clinical Trials Information
- 16.51.4. Safety and Efficacy
- 16.52. SOTEVTAMAB (AB-16B5): ALETHIA BIOTHERAPEUTICS
- 16.52.1. Product Description
- 16.52.2. Other Developmental Activities
- 16.52.3. Clinical Development
- 16.52.3.1. Clinical Trials Information
- 16.52.4. Safety and Efficacy
- 16.53. AVUTOMETINIB (VS-6766): VERASTEM ONCOLOGY
- 16.53.1. Product Description
- 16.53.2. Other Developmental Activities
- 16.53.3. Clinical Development
- 16.53.3.1. Clinical Trial Information
- 16.53.4. Safety and Efficacy
- 16.54. FF-10832: FUJIFILM CORPORATION
- 16.54.1. Product Description
- 16.54.2. Other Developmental Activities
- 16.54.3. Clinical Development
- 16.54.3.1. Clinical Trials Information
- 16.54.4. Safety and Efficacy
- 16.55. NAPTUMOMAB ESTAFENATOX (NAP): NEOTX THERAPEUTICS/ ACTIVE BIOTECH
- 16.55.1. Product Description
- 16.55.2. Other Developmental Activity
- 16.55.3. Clinical Development
- 16.55.3.1. Clinical Trials Information
- 16.55.4. Safety and Efficacy
- 16.56. BNT116: BIONTECH SE/REGENERON PHARMACEUTICALS
- 16.56.1. Product Description
- 16.56.2. Other Developmental Activities
- 16.56.3. Clinical Development
- 16.56.3.1. Clinical Trials Information
- 16.56.4. Safety and Efficacy
- 16.57. VEPAFESTINIB (TAS0953/HM06): TAIHO PHARMACEUTICAL AND HELSINN HEALTHCARE
- 16.57.1. Product Description
- 16.57.2. Other Developmental Activities
- 16.57.3. Clinical Development
- 16.57.3.1. Clinical Trials Information
- 16.57.4. Safety and Efficacy
- 16.58. EP0031 (A400): ELLIPSES PHARMA/KELUN-BIOTECH
- 16.58.1. Product Description
- 16.58.2. Other Developmental Activities
- 16.58.3. Clinical Development
- 16.58.3.1. Clinical Trials Information
- 16.58.4. Safety and Efficacy
- 16.59. PAMVATAMIG (MCLA-129): MERUS
- 16.59.1. Product Description
- 16.59.2. Other Developmental Activities
- 16.59.3. Clinical Development
- 16.59.3.1. Clinical Trials Information
- 16.59.4. Safety and Efficacy
- 16.6. DUPERT (FULZERASIB): GENFLEET THERAPEUTICS
- 16.60.1. Product Description
- 16.60.2. Other Developmental Activities
- 16.60.3. Clinical Development
- 16.60.3.1. Clinical Trials Information
- 16.60.4. Safety and Efficacy
- 16.61. REQORSA (QUARATUSUGENE OZEPLASMID): GENPREX
- 16.61.1. Product Description
- 16.61.2. Other Developmental Activities
- 16.61.3. Clinical Development
- 16.61.3.1. Clinical Trial Information
- 16.61.4. Safety and Efficacy
- 16.62. ZIDESAMTINIB (NVL-520): NUVALENT
- 16.62.1. Product Description
- 16.62.2. Other Developmental Activities
- 16.62.3. Clinical Development
- 16.62.3.1. Clinical Trials Information
- 16.62.4. Safety and Efficacy
- 16.63. NVL-655: NUVALENT
- 16.63.1. Product Description
- 16.63.2. Other Developmental Activities
- 16.63.3. Clinical Development
- 16.63.3.1. Clinical Trials Information
- 16.63.4. Safety and Efficacy
- 16.64. PDC*LUNG01: PDC*LINE PHARMA
- 16.64.1. Product Description
- 16.64.2. Other Developmental Activities
- 16.64.3. Clinical Development
- 16.64.3.1. Clinical Trials Information
- 16.64.4. Safety and Efficacy
- 16.65. TAS3351: TAIHO ONCOLOGY
- 16.65.1. Product Description
- 16.65.2. Other Developmental Activities
- 16.65.3. Clinical Development
- 16.65.3.1. Clinical Trials Information
- 16.65.4. Safety and Efficacy
- 16.66. SABESTOMIG (AZD7789): ASTRAZENECA
- 16.66.1. Product Description
- 16.66.2. Other Developmental Activities
- 16.66.3. Clinical Development
- 16.66.3.1. Clinical Trials Information
- 16.66.4. Safety and Efficacy
- 16.67. SELVIGALTIN (GB1211): GALECTO BIOTECH
- 16.67.1. Product Description
- 16.67.2. Other Developmental Activities
- 16.67.3. Clinical Development
- 16.67.3.1. Clinical Trials Information
- 16.67.4. Safety and Efficacy
- 16.68. JIN-A02: J INTS BIO
- 16.68.1. Product Description
- 16.68.2. Other Developmental Activities
- 16.68.3. Clinical Development
- 16.68.3.1. Clinical Trials Information
- 16.68.4. Safety and Efficacy
- 16.69. SASANLIMAB: PFIZER
- 16.69.1. Product Description
- 16.69.2. Clinical Development
- 16.69.2.1. Clinical Trials Information
- 16.69.3. Safety and Efficacy
17. NSCLC: 7MM MARKET ANALYSIS
- 17.1. KEY FINDINGS
- 17.2. TOTAL MARKET SIZE OF NSCLC BY COUNTRY IN THE 7MM
- 17.3. TOTAL MARKET SIZE OF NSCLC BY BIOMARKER IN THE 7MM
- 17.4. MARKET OULOOK
- 17.4.1. PD-L1 Expression
- 17.4.2. EGFR Mutation
- 17.4.3. ALK Mutation
- 17.4.4. KRAS Mutation
- 17.4.5. BRAF Mutation
- 17.4.6. MET Mutation
- 17.4.7. Others Emerging Biomarkers
- 17.5. KEY MARKET FORECAST ASSUMPTIONS
- 17.5.1. PD-L1 Expression
- 17.5.2. EGFR-mutated NSCLC
- 17.5.3. ALK-mutated NSCLC
- 17.5.4. KRAS Fusion NSCLC
- 17.5.5. ROS1 NSCLC
- 17.5.6. HER2-mutated NSCLC
- 17.5.7. BRAF-mutated NSCLC
- 17.5.8. C-MET-mutated NSCLC
- 17.5.9. RET-mutated NSCLC
- 17.5.10. NTRK-mutated NSCLC
- 17.5.11. Advanced NRG1 Fusion NSCLC
- 17.6. THE UNITED STATES
- 17.6.1. Advanced NRG1 Fusion NSCLC
- 17.6.1.1. Total Market Size of Advanced NRG1 Fusion NSCLC in the United States
- 17.6.1.2. Market Size of Advanced NRG1 Fusion NSCLC by Therapies in the United States
- 17.6.2. RET Fusion NSCLC
- 17.6.2.1. Total Market Size of RET Fusion NSCLC in the United States
- 17.6.2.2. Market Size of RET Fusion NSCLC by Therapies in the United States
- 17.6.3. NTRK1/2/3 Gene Fusion NSCLC
- 17.6.3.1. Total Market Size of NTRK1/2/3 Gene Fusion NSCLC in the United States
- 17.6.3.2. Market Size of NTRK1/2/3 Gene Fusion NSCLC by Therapies in the United States
- 17.6.4. BRAF NSCLC
- 17.6.4.1. Total Market Size of BRAF NSCLC in the United States
- 17.6.4.2. Market Size of BRAF NSCLC by Therapies in the United States
- 17.6.5. c-MET NSCLC
- 17.6.5.1. Total Market Size of c-MET NSCLC in the United States
- 17.6.5.2. Market Size of c-MET NSCLC by Therapies in the United States
- 17.6.6. PD-L1 NSCLC
- 17.6.6.1. Total Market Size of PD-L1 NSCLC in the United States
- 17.6.6.2. Market Size of PD-L1 NSCLC by Therapies in the United States
- 17.6.7. ALK NSCLC
- 17.6.7.1. Total Market Size of ALK NSCLC in the United States
- 17.6.7.2. Market Size of ALK NSCLC by Therapies in the United States
- 17.6.8. KRAS NSCLC
- 17.6.8.1. Total Market Size of KRAS NSCLC in the United States
- 17.6.8.2. Market Size of KRAS NSCLC by Therapies in the United States
- 17.6.9. EGFR NSCLC
- 17.6.9.1. Total Market Size of EGFR NSCLC in the United States
- 17.6.9.2. Market Size of EGFR NSCLC by Therapies in the United States
- 17.6.10. ROS-1 NSCLC
- 17.6.10.1. Total Market Size of ROS-1 NSCLC in the United States
- 17.6.10.2. Market Size of ROS-1 NSCLC by Therapies in the United States
- 17.6.11. HER2 NSCLC
- 17.6.11.1. Total Market Size of HER2 NSCLC in the United States
- 17.6.11.2. Market Size of HER2 NSCLC by Therapies in the United States
- 17.7. EU4 AND THE UK
- 17.7.1. Advanced NRG1 Fusion NSCLC
- 17.7.1.1. Total Market Size of Advanced NRG1 Fusion NSCLC in EU4 and the UK
- 17.7.1.2. Market Size of Advanced NRG1 fusion NSCLC by Therapies in EU4 and the UK
- 17.7.2. RET Fusion NSCLC
- 17.7.2.1. Total Market Size of RET Fusion NSCLC in EU4 and the UK
- 17.7.2.2. Market Size of RET fusion NSCLC by Therapies in EU4 and the UK
- 17.7.3. NTRK1/2/3 Gene Fusion NSCLC
- 17.7.3.1. Total Market Size of NTRK1/2/3 Gene Fusion NSCLC in EU4 and the UK
- 17.7.3.2. Market Size of NTRK1/2/3 Gene fusion NSCLC by Therapies in EU4 and the UK
- 17.7.4. BRAF NSCLC
- 17.7.4.1. Total Market Size of BRAF NSCLC in EU4 and the UK
- 17.7.4.2. Market Size of BRAF NSCLC by Therapies in EU4 and the UK
- 17.7.5. c-MET NSCLC
- 17.7.5.1. Total Market Size of c-MET NSCLC in EU4 and the UK
- 17.7.5.2. Market Size of c-MET NSCLC by Therapies in EU4 and the UK
- 17.7.6. PD-L1 NSCLC
- 17.7.6.1. Total Market Size of PD-L1 NSCLC in EU4 and the UK
- 17.7.6.2. Market Size of PD-L1 NSCLC by Therapies in EU4 and the UK
- 17.7.7. ALK NSCLC
- 17.7.7.1. Total Market Size of ALK NSCLC in EU4 and the UK
- 17.7.7.2. Market Size of ALK NSCLC by Therapies in EU4 and the UK
- 17.7.8. EGFR NSCLC
- 17.7.8.1. Total Market Size of EGFR NSCLC in EU4 and the UK
- 17.7.8.2. Market Size of EGFR NSCLC by Therapies in EU4 and the UK
- 17.7.9. KRAS NSCLC
- 17.7.9.1. Total Market Size of KRAS NSCLC in EU4 and the UK
- 17.7.9.2. Market Size of KRAS NSCLC by Therapies in EU4 and the UK
- 17.7.10. ROS-1 NSCLC
- 17.7.10.1. Total Market Size of ROS-1 NSCLC in EU4 and the UK
- 17.7.10.2. Market Size of ROS-1 NSCLC by Therapies in EU4 and the UK
- 17.7.11. HER2 NSCLC
- 17.7.11.1. Total Market Size of HER2 NSCLC in EU4 and the UK
- 17.7.11.2. Market Size of HER2 NSCLC by Therapies in EU4 and the UK
- 17.8. JAPAN
- 17.8.1. Advanced NRG1 fusion NSCLC
- 17.8.1.1. Total Market Size of Advanced NRG1 fusion NSCLC in Japan
- 17.8.1.2. Market Size of Advanced NRG1 Fusion NSCLC by Therapies in Japan
- 17.8.2. RET fusion NSCLC
- 17.8.2.1. Total Market Size of RET fusion NSCLC in Japan
- 17.8.2.2. Market Size of RET Fusion NSCLC by Therapies in Japan
- 17.8.3. NTRK1/2/3 Gene fusion NSCLC
- 17.8.3.1. Total Market Size of NTRK1/2/3 Gene fusion NSCLC in Japan
- 17.8.3.2. Market Size of NTRK1/2/3 Gene Fusion NSCLC by Therapies in Japan
- 17.8.4. BRAF NSCLC
- 17.8.4.1. Total Market Size of BRAF NSCLC in Japan
- 17.8.4.2. Market Size of BRAF NSCLC by Therapies in Japan
- 17.8.5. c-MET NSCLC
- 17.8.5.1. Total Market Size of c-MET NSCLC in Japan
- 17.8.5.2. Market Size of c-MET NSCLC by Therapies in Japan
- 17.8.6. PD-L1 NSCLC
- 17.8.6.1. Total Market Size of PD-L1 NSCLC in Japan
- 17.8.6.2. Market Size of PD-L1 NSCLC by Therapies in Japan
- 17.8.7. ALK NSCLC
- 17.8.7.1. Total Market Size of ALK NSCLC in Japan
- 17.8.7.3. Market Size of ALK NSCLC by Therapies in Japan
- 17.8.8. KRAS NSCLC
- 17.8.8.1. Total Market Size of KRAS NSCLC in Japan
- 17.8.8.2. Market Size of KRAS NSCLC by Therapies in Japan
- 17.8.9. EGFR NSCLC
- 17.8.9.1. Total Market Size of EGFR NSCLC in Japan
- 17.8.9.3. Market Size of EGFR NSCLC by Therapies in Japan
- 17.8.10. ROS-1 NSCLC
- 17.8.10.1. Total Market Size of ROS-1 NSCLC in Japan
- 17.8.10.2. Market Size of ROS-1 NSCLC by Therapies in Japan
- 17.8.11. HER2 NSCLC
- 17.8.11.1. Total Market Size of HER2 NSCLC in Japan
- 17.8.11.2. Market Size of HER2 NSCLC by Therapies in Japan
18. UNMET NEEDS
19. SWOT ANALYSIS
20. KOL VIEWS
21. MARKET ACCESS AND REIMBURSEMENT
- 21.1. PATIENT ACCESS PROGRAM
- 21.2. INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE (IQWIG): GERMANY
- 21.3. NSCLC REIMBURSEMENT IN FRANCE
- 21.4. ITALIAN MEDICINES AGENCY (AIFA): ITALY
- 21.5. NSCLC REIMBURSEMENT IN SPAIN
- 21.6. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE): THE UK
- 21.7. REIMBURSEMENT STATUS OF LUNG CANCER DRUGS IN JAPAN
22. APPENDIX
- 22.1. BIBLIOGRAPHY
- 22.2. REPORT METHODOLOGY
23. DELVEINSIGHT CAPABILITIES
24. DISCLAIMER
25. ABOUT DELVEINSIGHT
